Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays
Abstract This study focuses on refining growth-rate-based drug response metrics for patient-derived tumor organoid screening using brightfield live-cell imaging. Traditional metrics like Normalized Growth Rate Inhibition (GR) and Normalized Drug Response (NDR) have been used to assess organoid respo...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | Communications Biology |
| Online Access: | https://doi.org/10.1038/s42003-024-07329-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850136928460996608 |
|---|---|
| author | Christophe Deben Edgar Cardenas De La Hoz Felicia Rodrigues Fortes Maxim Le Compte Sofie Seghers Steve Vanlanduit Hendrik Vercammen Bert Van Den Bogert Nelson Dusetti Abraham Lin Geert Roeyen Marc Peeters Hans Prenen Filip Lardon Evelien Smits |
| author_facet | Christophe Deben Edgar Cardenas De La Hoz Felicia Rodrigues Fortes Maxim Le Compte Sofie Seghers Steve Vanlanduit Hendrik Vercammen Bert Van Den Bogert Nelson Dusetti Abraham Lin Geert Roeyen Marc Peeters Hans Prenen Filip Lardon Evelien Smits |
| author_sort | Christophe Deben |
| collection | DOAJ |
| description | Abstract This study focuses on refining growth-rate-based drug response metrics for patient-derived tumor organoid screening using brightfield live-cell imaging. Traditional metrics like Normalized Growth Rate Inhibition (GR) and Normalized Drug Response (NDR) have been used to assess organoid responses to anticancer treatments but face limitations in accurately quantifying cytostatic and cytotoxic effects across varying growth rates. Here, we introduce the Normalized Organoid Growth Rate (NOGR) metric, specifically developed for brightfield imaging-based assays. A label-free image analysis model was applied to segment organoids precisely, track their growth rates over time, and classify viable and dead organoids. Testing eleven phenotypically distinct pancreatic cancer organoid models with five chemotherapeutics demonstrates that the NOGR metric more effectively captures cytostatic and cytotoxic drug effects compared to existing methods. This approach enhances the biological relevance of drug sensitivity assessments on organoids and offers a valuable tool for advancing personalized cancer treatment strategies. |
| format | Article |
| id | doaj-art-ccaa7af0afca4fca9dfbdb7f33073087 |
| institution | OA Journals |
| issn | 2399-3642 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Communications Biology |
| spelling | doaj-art-ccaa7af0afca4fca9dfbdb7f330730872025-08-20T02:30:59ZengNature PortfolioCommunications Biology2399-36422024-12-017111110.1038/s42003-024-07329-5Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assaysChristophe Deben0Edgar Cardenas De La Hoz1Felicia Rodrigues Fortes2Maxim Le Compte3Sofie Seghers4Steve Vanlanduit5Hendrik Vercammen6Bert Van Den Bogert7Nelson Dusetti8Abraham Lin9Geert Roeyen10Marc Peeters11Hans Prenen12Filip Lardon13Evelien Smits14Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of AntwerpIndustrial Vision Lab, University of AntwerpCenter for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of AntwerpCenter for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of AntwerpCenter for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of AntwerpIndustrial Vision Lab, University of AntwerpAntwerp Research Group for Ocular Science (ARGOS), Translational Neurosciences, Faculty of Medicine and Health Sciences, University of AntwerpAntwerp Research Group for Ocular Science (ARGOS), Translational Neurosciences, Faculty of Medicine and Health Sciences, University of AntwerpCentre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-CalmettesCenter for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of AntwerpCenter for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of AntwerpCenter for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of AntwerpCenter for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of AntwerpCenter for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of AntwerpCenter for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of AntwerpAbstract This study focuses on refining growth-rate-based drug response metrics for patient-derived tumor organoid screening using brightfield live-cell imaging. Traditional metrics like Normalized Growth Rate Inhibition (GR) and Normalized Drug Response (NDR) have been used to assess organoid responses to anticancer treatments but face limitations in accurately quantifying cytostatic and cytotoxic effects across varying growth rates. Here, we introduce the Normalized Organoid Growth Rate (NOGR) metric, specifically developed for brightfield imaging-based assays. A label-free image analysis model was applied to segment organoids precisely, track their growth rates over time, and classify viable and dead organoids. Testing eleven phenotypically distinct pancreatic cancer organoid models with five chemotherapeutics demonstrates that the NOGR metric more effectively captures cytostatic and cytotoxic drug effects compared to existing methods. This approach enhances the biological relevance of drug sensitivity assessments on organoids and offers a valuable tool for advancing personalized cancer treatment strategies.https://doi.org/10.1038/s42003-024-07329-5 |
| spellingShingle | Christophe Deben Edgar Cardenas De La Hoz Felicia Rodrigues Fortes Maxim Le Compte Sofie Seghers Steve Vanlanduit Hendrik Vercammen Bert Van Den Bogert Nelson Dusetti Abraham Lin Geert Roeyen Marc Peeters Hans Prenen Filip Lardon Evelien Smits Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays Communications Biology |
| title | Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays |
| title_full | Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays |
| title_fullStr | Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays |
| title_full_unstemmed | Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays |
| title_short | Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays |
| title_sort | development and validation of the normalized organoid growth rate nogr metric in brightfield imaging based assays |
| url | https://doi.org/10.1038/s42003-024-07329-5 |
| work_keys_str_mv | AT christophedeben developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT edgarcardenasdelahoz developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT feliciarodriguesfortes developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT maximlecompte developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT sofieseghers developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT stevevanlanduit developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT hendrikvercammen developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT bertvandenbogert developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT nelsondusetti developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT abrahamlin developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT geertroeyen developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT marcpeeters developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT hansprenen developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT filiplardon developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays AT eveliensmits developmentandvalidationofthenormalizedorganoidgrowthratenogrmetricinbrightfieldimagingbasedassays |